Align Technology, Envista, Centene, Amphastar Pharmaceuticals, and Oscar Health Shares Plummet, What You Need To Know

What Happened?

A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 

The president's tone and the suggestion of canceling a meeting with President Xi caused a rapid sell-off in the market. The trade dispute flared up after China imposed export controls on rare earth minerals, which are critical components for high-tech manufacturing. The escalation of the trade war raises concerns about supply chain disruptions and increased costs for technology companies, which are heavily reliant on global trade, leading to a broad sell-off in the sector.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

Among others, the following stocks were impacted:

• Dental Equipment & Technology company Align Technology (NASDAQ:ALGN) fell 4.5%. Is now the time to buy Align Technology? Access our full analysis report here, it’s free for active Edge members.
• Dental Equipment & Technology company Envista (NYSE:NVST) fell 5.1%. Is now the time to buy Envista? Access our full analysis report here, it’s free for active Edge members.
• Health Insurance Providers company Centene (NYSE:CNC) fell 4.1%. Is now the time to buy Centene? Access our full analysis report here, it’s free for active Edge members.
• Generic Pharmaceuticals company Amphastar Pharmaceuticals (NASDAQ:AMPH) fell 5.2%. Is now the time to buy Amphastar Pharmaceuticals? Access our full analysis report here, it’s free for active Edge members.
• Health Insurance Providers company Oscar Health (NYSE:OSCR) fell 6.5%. Is now the time to buy Oscar Health? Access our full analysis report here, it’s free for active Edge members.

Zooming In On Oscar Health (OSCR)

Oscar Health’s shares are extremely volatile and have had 65 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 8 days ago when the stock gained 3.1% as news of a new sgovernment prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations. The pharmaceutical and biotech sectors rallied for a second consecutive day following the announcement of a direct-to-consumer prescription drug selling website. A key driver for the optimism is a deal between Pfizer and the administration, allowing the company to avoid potential tariffs by reducing drug prices. This outcome is seen as a relief for the industry, which had braced for more severe measures. The move has reduced uncertainty in the sector, with other major players like Eli Lilly reportedly in negotiations for a similar agreement, signaling a potentially favorable new landscape for drugmakers.

Oscar Health is up 38.6% since the beginning of the year, but at $18.79 per share, it is still trading 16.4% below its 52-week high of $22.47 from October 2025. Investors who bought $1,000 worth of Oscar Health’s shares at the IPO in March 2021 would now be looking at an investment worth $539.80.

Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.